Checking Boxes Toward Consumer Health Spinoff, J&J Notes Costs For Preparing To Change
Executive Summary
Firm adds outside-the-box details about planned spinoff with its third quarter results on 18 October, which included worldwide consumer results slipping 0.4% to $3.8bn on a 2.1% increase in the offset by 2.3% international decline.
You may also be interested in...
J&J Limited On Offering Consumer Business Separation Details, Clear On Q4 Revenue Drag
“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.
US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.
Strongest US Cough/Cold Season In 10 Years Likely
Increasing numbers cough/cold drug prescriptions combined with consumers’ waning interest in flu vaccines point to 2022-2023 season rivaling decade-high levels from 2017-18 and to retailers boosting inventories through year-end, Raymond James analysts say.